Another Antibiotic Success Story as Tetraphase's Eravacycline Meets Goal
Three antibiotics in just over a week have impressed in Phase III trials, with Tetraphase, The Medicines Company and Paratek all confident of being on the market in the next year
You may also be interested in...
Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala
The latest drug development news and highlights from our US FDA Performance Tracker.
Company presents game plan for targeting 1,900 high-prescribing hospitals in US in a launch kicking off in the second half of October.
As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.